Managing clotting: A North American perspective

Current Opinion in Anaesthesiology

Volumn 25, Issue 1, 2012, Pages 74-79

  Sniecinski, Roman M ^a   Karkouti, Keyvan ^b,c   Levy, Jerrold H ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

antifibrinolytics; aprotinin; bleeding; coagulopathy; desmopressin; factor VIIa; fibrinogen; protamine; recombinant coagulation products

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 9 COMPLEX; CLOPIDOGREL; DESMOPRESSIN; FIBRINOGEN; FRESH FROZEN PLASMA; GELATIN SPONGE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MICROCRYSTALLINE COLLAGEN; PLACEBO; PRASUGREL; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBIN; THROMBIN; TICAGRELOR; TRANEXAMIC ACID;

ACIDOSIS; ANAPHYLAXIS; ARTERY THROMBOSIS; BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD TRANSFUSION; DRUG MEGADOSE; DRUG PROTEIN BINDING; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEMOPHILIA; HEMOSTASIS; HUMAN; HYPOTENSION; HYPOTHERMIA; LUNG VASOCONSTRICTION; MASSIVE TRANSFUSION COAGULOPATHY; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VENOUS THROMBOEMBOLISM;

ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD TRANSFUSION; FACTOR VIIA; HEMOSTATIC TECHNIQUES; HEMOSTATICS; HUMANS; NORTH AMERICA; PLATELET FUNCTION TESTS; PROTAMINES;

EID: 84855774361     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32834ebd59     Document Type: Review

References (32)

1. Sniecinski RM, Levy JH. Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg 2011; 113:1319-1333.
2. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301-2311. (Pubitemid 46849160)
3. Steiner ME, Despotis GJ. Transfusion algorithms and how they apply to blood conservation: the high-risk cardiac surgical patient. Hematol Oncol Clin North Am 2007; 21:177-184. (Pubitemid 46156985)
4. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastographyguided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88:312-319. (Pubitemid 29070189)
5. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106:1366-1375. (Pubitemid 351571062)
6. Holcomb JB. Optimal use of blood products in severely injured trauma patients. Hematol Am Soc Hematol Educ Program 2010; 2010:465-469.
7. Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma 2009; 66:1616-1624.
8. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001; 72:S1814-S1820. (Pubitemid 33049833)
9. Levy JH, Tanaka KA, Steiner ME. Evaluation and management of bleeding during cardiac surgery. Curr Hematol Rep 2005; 4:368-372.
10. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376:23-32.
11. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354:1940-1947.
12. Sniecinski RM, Chen EP, Makadia SS, et al. Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth 2010; 24:959-963.
13. Martin K, Wiesner G, Breuer T, et al. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107:1783-1790.
14. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353-365. (Pubitemid 43145060)
15. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-2331. (Pubitemid 351749156)
16. FDA. (2008). Questions and Answers on Aprotinin (marketed as Trasylol). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor- PatientsandProviders/ucm142740.htm. [Accessed 5 December 2011]
17. Karkouti K, Wijeysundera DN, Yau TM, et al. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010; 110:21-29.
18. Szabo G, Veres G, Radovits T, et al. Effects of novel synthetic serine protease inhibitors on postoperative blood loss, coagulation parameters, and vascular relaxation after cardiac surgery. J Thorac Cardiovasc Surg 2010; 139:181- 188; discussion 188.
19. Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg 2008; 106:392-403. (Pubitemid 351156659)
20. Kuitunen AH, Salmenpera MT, Heinonen J, et al. Heparin rebound: a comparative study of protamine chloride and protamine sulfate in patients undergoing coronary artery bypass surgery. J Cardiothorac VascAnesth1991; 5:221-226.
21. Levy JH, Schwieger IM, Zaidan JR, et al. Evaluation of patients at risk for protamine reactions. J Thorac Cardiovasc Surg 1989; 98:200-204. (Pubitemid 19198523)
22. Levy JH, Zaidan JR, Faraj B. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes. Anesth Analg 1986; 65:739-742. (Pubitemid 16085789)
23. Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117:6777-6785.
24. Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. Thromb Haemost 1994; 71:154-155.
25. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93:1101-1107. (Pubitemid 40823515)
26. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5:266-273. (Pubitemid 46139450)
27. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44:1325-1331. (Pubitemid 39129245)
28. Karkouti K, Levy JH. Recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg 2011; 113:711-712.
29. OConnell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. J Am Med Assoc 2006; 295:293-298. (Pubitemid 43112957)
30. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791-1800.
31. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109:918-926.
32. Achneck HE, Sileshi B, Jamiolkowski RM, et al. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010; 251:217-228.